Tilman Robinson1, Ahmed Abdelhak2, Tanima Bose3, Edgar Meinl3, Markus Otto2, Uwe K Zettl4, Rick Dersch1, Hayrettin Tumani2,5, Sebastian Rauer1, André Huss2. 1. Clinic of Neurology and Neurophysiology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany. 2. Department of Neurology, University Hospital Ulm, 89081 Ulm, Germany. 3. Biomedical Center and Klinikum Grosshadern, Institute of Clinical Neuroimmunology, Ludwig Maximilian University, 81377 Munich, Germany. 4. Neuroimmunological Section, Department of Neurology, Medical Center of the University of Rostock, 18051 Rostock, Germany. 5. Specialty Hospital Dietenbronn, 88477 Schwendi, Germany.
Abstract
The MRZ reaction (MRZR) comprises the three antibody indices (AIs) against measles, rubella, and varicella zoster virus, reflecting an intrathecal polyspecific B cell response highly specific for multiple sclerosis (MS). Thus, MRZR can be used to confirm a diagnosis of primary progressive MS (PPMS) but its pathophysiological and wider clinical relevance is unclear. This study aimed to investigate whether PPMS patients with a positive MRZR (MRZR+) differ from those with a negative MRZR (MRZR-) according to cerebrospinal fluid (CSF) biomarkers of B cell activity, neuroaxonal damage or glial activity, and clinical features. (1) Methods: In a multicenter PPMS cohort (n = 81) with known MRZR status, we measured B cell-activating factor (BAFF), chemokine CXC ligand 13 (CXCL-13), soluble B cell maturation antigen (sBCMA), soluble transmembrane activator and CAML interactor (sTACI), and chitinase-3-like protein 1 (CHI3L1) in the CSF with enzyme-linked immunosorbent assays (ELISAs). Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were detected in serum and CSF using single molecule array (SIMOA) technology. (2) Results: MRZR+ patients (45.7% of all PPMS patients) revealed higher levels of NfL in CSF compared to MRZR- patients (54.3%). There were positive correlations between each of sBCMA, sTACI, and intrathecal immunoglobin G (IgG) synthesis. Additionally, NfL concentrations in serum positively correlated with those in CSF and those of GFAP in serum. However, MRZR+ and MRZR- patients did not differ concerning clinical features (e.g., age, disease duration, Expanded Disability Status Scale (EDSS) at diagnosis and follow-up); CSF routine parameters; CSF concentrations of BAFF, CXCL-13, sBCMA, sTACI, CHI3L1, and GFAP; or serum concentrations of GFAP and NfL. (3) Conclusions: In PPMS patients, MRZR positivity might indicate a more pronounced axonal damage. Higher levels of the soluble B cell receptors BCMA and transmembrane activator and CAML interactor (TACI) in CSF are associated with a stronger intrathecal IgG synthesis in PPMS.
The MRZ reaction (MRZR) comprises the three antibody indices (AIs) against measles, rubella, and varicella zoster virus, reflecting an intrathecal polyspecific B cell response highly specific for multiple sclerosis (MS). Thus, MRZR can be used to confirm a diagnosis of primary progressive MS (PPMS) but its pathophysiological and wider clinical relevance is unclear. This study aimed to investigate whether PPMS patients with a positive MRZR (MRZR+) differ from those with a negative MRZR (MRZR-) according to cerebrospinal fluid (CSF) biomarkers of B cell activity, neuroaxonal damage or glial activity, and clinical features. (1) Methods: In a multicenter PPMS cohort (n = 81) with known MRZR status, we measured B cell-activating factor (BAFF), chemokine CXC ligand 13 (CXCL-13), soluble B cell maturation antigen (sBCMA), soluble transmembrane activator and CAML interactor (sTACI), and chitinase-3-like protein 1 (CHI3L1) in the CSF with enzyme-linked immunosorbent assays (ELISAs). Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were detected in serum and CSF using single molecule array (SIMOA) technology. (2) Results: MRZR+ patients (45.7% of all PPMS patients) revealed higher levels of NfL in CSF compared to MRZR- patients (54.3%). There were positive correlations between each of sBCMA, sTACI, and intrathecal immunoglobin G (IgG) synthesis. Additionally, NfL concentrations in serum positively correlated with those in CSF and those of GFAP in serum. However, MRZR+ and MRZR- patients did not differ concerning clinical features (e.g., age, disease duration, Expanded Disability Status Scale (EDSS) at diagnosis and follow-up); CSF routine parameters; CSF concentrations of BAFF, CXCL-13, sBCMA, sTACI, CHI3L1, and GFAP; or serum concentrations of GFAP and NfL. (3) Conclusions: In PPMS patients, MRZR positivity might indicate a more pronounced axonal damage. Higher levels of the soluble B cell receptors BCMA and transmembrane activator and CAML interactor (TACI) in CSF are associated with a stronger intrathecal IgG synthesis in PPMS.
Entities:
Keywords:
B cell-activating factor (BAFF); MRZ reaction (MRZR); chemokine CXC ligand 13 (CXCL-13); chitinase-3-like protein 1 (CHI3L1); glial fibrillary acidic protein (GFAP); neurofilament light chain (NfL); primary progressive multiple sclerosis (PPMS); soluble B cell maturation antigen (sBCMA); soluble transmembrane activator and CAML interactor (sTACI)
Authors: Franziska S Hoffmann; Peer-Hendrik Kuhn; Sarah A Laurent; Stefanie M Hauck; Kerstin Berer; Simone A Wendlinger; Markus Krumbholz; Mohsen Khademi; Tomas Olsson; Martin Dreyling; Hans-Walter Pfister; Tobias Alexander; Falk Hiepe; Tania Kümpfel; Howard C Crawford; Hartmut Wekerle; Reinhard Hohlfeld; Stefan F Lichtenthaler; Edgar Meinl Journal: J Immunol Date: 2014-12-10 Impact factor: 5.422
Authors: C E Teunissen; A Petzold; J L Bennett; F S Berven; L Brundin; M Comabella; D Franciotta; J L Frederiksen; J O Fleming; R Furlan; R Q Hintzen; S G Hughes; M H Johnson; E Krasulova; J Kuhle; M C Magnone; C Rajda; K Rejdak; H K Schmidt; V van Pesch; E Waubant; C Wolf; G Giovannoni; B Hemmer; H Tumani; F Deisenhammer Journal: Neurology Date: 2009-12-01 Impact factor: 9.910
Authors: M Alba Mañé Martínez; Bob Olsson; Laura Bau; Elisabet Matas; Álvaro Cobo Calvo; Ulf Andreasson; Kaj Blennow; Lucia Romero-Pinel; Sergio Martínez-Yélamos; Henrik Zetterberg Journal: Mult Scler Date: 2015-03-02 Impact factor: 6.312
Authors: Sara Gil-Perotin; Jessica Castillo-Villalba; Laura Cubas-Nuñez; Raquel Gasque; David Hervas; Josep Gomez-Mateu; Carmen Alcala; Francisco Perez-Miralles; Francisco Gascon; Jose Andres Dominguez; Bonaventura Casanova Journal: Front Neurol Date: 2019-09-23 Impact factor: 4.003
Authors: Lenka Novakova; Henrik Zetterberg; Peter Sundström; Markus Axelsson; Mohsen Khademi; Martin Gunnarsson; Clas Malmeström; Anders Svenningsson; Tomas Olsson; Fredrik Piehl; Kaj Blennow; Jan Lycke Journal: Neurology Date: 2017-10-27 Impact factor: 9.910